No Data
No Data
Mesoblast Refiles Biological License Application With the Us FDA for Cell Therapy; Shares Fall 6%
Mesoblast (ASX:MSB) refiled the biological license application with the US Food and Drug Administration for the use of its Ryoncil-branded remestemcel-L cell therapy in pediatric patients with steroid
What's Going on With the Mesoblast Share Price Today?
The Mesoblast Ltd (ASX: MSB) share price is having a disappointing session on Tuesday.
Mesoblast Resubmits Biologics License Application (BLA) With United States Food & Drug Administration (FDA) for Approval of Ryoncil in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its BLA for approval of Ryoncil (remestemcel-L) in the treatment of children with SR-aGVHD.
Express News | Mesoblast Ltd - Mesoblast Resubmits Bla With FDA for Ryoncil Approval
Mesoblast to File Biological License Application With US FDA for Cellular Therapy
Mesoblast (ASX:MSB) is set to file a biological license application for the Ryoncil-branded cellular therapy remestemcel-L with the US Food and Drug Administration in the coming week, according to a f
ASX Growth Companies With High Insider Ownership And At Least 26% Earnings Growth
Amidst a generally downward trend in the ASX200, with notable dips in sectors like materials and utilities, there are still segments showing resilience, such as industrials.
No Data
Aariya : how good it come back to 1.10 definitely going up